Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18474321 | 0.86 | ADRB2 (0.48) | HTR6ADRB2GSK3BDRD2SLC6A4 | |
| SCHEMBL6638973 | 0.83 | ADRB2 (0.45) | HTR6ADRB2GSK3BDRD2SLC6A4 | |
| SCHEMBL21384653 | 0.81 | KCNH2 (0.62) | HTR6APPHTR2CDRD2SLC6A4 | |
| SCHEMBL4675116 | 0.81 | SLC6A4 (0.66) | HTR6APPDRD2SLC6A4KCNH2 | |
| SCHEMBL21088053 | 0.81 | APP (0.50) | HTR6APPHTR2CGSK3BDRD2 | |
| Hydrochloric Acid SCHEMBL30611179 | 0.80 | SLC6A4 (0.64) | HTR6APPDRD2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL26912351 | 0.80 | SLC6A4 (0.64) | HTR6APPDRD2SLC6A4KCNH2 | |
| SCHEMBL206108 | 0.78 | APP (0.51) | HTR6APPDRD2SLC6A4KCNH2 | |
| SCHEMBL18441414 | 0.77 | ADRB2 (0.45) | HTR6ADRB2GSK3BDRD2SLC6A4 | |
| SCHEMBL5937271 | 0.77 | HTR6 (0.57) | HTR6APPHTR2CADRB2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7491729-B2 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBOTT GMBH & CO. KG (DE) | 2009-02-17 | — | — | US | disclosed |
| EP-1572698-B1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO¬2,3-D PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR6 1/4885APP 878/4885HTR2C 16/4885 |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | HTR3C, DRD3, HTR4 | HTR6 12/4885APP 3987/4885HTR2C 4/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR6 863/4885APP 2128/4885HTR2C 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.